Open Access

Role of apoptosis inhibitor of macrophages in patients with IgG4‑related disease/autoimmune pancreatitis and the clinical characteristics associated with this condition

  • Authors:
    • Shiroh Tanoue
    • Shuji Kanmura
    • Makoto Hinokuchi
    • Shiho Arima
    • Fumisato Sasaki
    • Shinichi Hashimoto
    • Akio Ido
  • View Affiliations

  • Published online on: August 24, 2022     https://doi.org/10.3892/br.2022.1565
  • Article Number: 82
  • Copyright: © Tanoue et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Type 1 autoimmune pancreatitis (AIP) is a pancreatic manifestation of IgG4‑related disease (IgG4‑RD) and is a unique chronic inflammatory disease characterized by fibrosis. IgG4‑RD is caused by an autoimmune mechanism that mimics malignant tumors and inflammatory disorders. Apoptosis inhibitor of macrophages (AIM) can function as a biomarker of autoimmune or inflammatory diseases with tissue fibrosis, including in inflammatory bowel disease and chronic liver disease. Therefore, the aim of the present study was to clarify the role of serum AIM levels and the clinical characteristics of patients with IgG4‑RD and AIP. For this purpose, serum AIM concentrations were assessed using ELISA and the association between AIM and the laboratory and clinical data from patients with IgG4‑RD/AIP, patients with pancreatic cancer (PC) and healthy controls (HCs), was determined. The results demonstrated that the serum AIM concentrations were not associated with the laboratory data. However, the serum AIM levels were significantly elevated in patients with AIP compared with the HCs and patients with PC. Furthermore, the serum AIM levels significantly decreased following steroid therapy in patients with AIP who were in remission. Overall, the present study demonstrates that serum AIM levels may be a potentially useful biomarker for the differential diagnosis of AIP and for evaluating the therapeutic reactivity of affected patients.

Related Articles

Journal Cover

October-2022
Volume 17 Issue 4

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tanoue S, Kanmura S, Hinokuchi M, Arima S, Sasaki F, Hashimoto S and Ido A: Role of apoptosis inhibitor of macrophages in patients with IgG4‑related disease/autoimmune pancreatitis and the clinical characteristics associated with this condition. Biomed Rep 17: 82, 2022
APA
Tanoue, S., Kanmura, S., Hinokuchi, M., Arima, S., Sasaki, F., Hashimoto, S., & Ido, A. (2022). Role of apoptosis inhibitor of macrophages in patients with IgG4‑related disease/autoimmune pancreatitis and the clinical characteristics associated with this condition. Biomedical Reports, 17, 82. https://doi.org/10.3892/br.2022.1565
MLA
Tanoue, S., Kanmura, S., Hinokuchi, M., Arima, S., Sasaki, F., Hashimoto, S., Ido, A."Role of apoptosis inhibitor of macrophages in patients with IgG4‑related disease/autoimmune pancreatitis and the clinical characteristics associated with this condition". Biomedical Reports 17.4 (2022): 82.
Chicago
Tanoue, S., Kanmura, S., Hinokuchi, M., Arima, S., Sasaki, F., Hashimoto, S., Ido, A."Role of apoptosis inhibitor of macrophages in patients with IgG4‑related disease/autoimmune pancreatitis and the clinical characteristics associated with this condition". Biomedical Reports 17, no. 4 (2022): 82. https://doi.org/10.3892/br.2022.1565